Morepen Laboratories Mar 2026: An ₹825 Cr CDMO Order Meets a 6.20% ROE

Section 1 — At a Glance

Morepen Laboratories closed FY26 with a stark dichotomy: top-line stagnation and bottom-line contraction paired with massive, forward-looking capital deployment. Consolidated revenue stood virtually flat at ₹1,806 Cr, while PAT contracted sharply to ₹96 Cr from ₹118 Cr the previous year. The market, however, is heavily distracted by the future. In February 2026, the company secured an ₹825 Cr international CDMO mandate, signaling a structural pivot from legacy generics to high-value manufacturing partnerships.

This transition is demanding severe upfront capital. The company raised ₹200 Cr via a QIP in August 2024, driving a surge in net block and capital work-in-progress, while borrowing scaled up from ₹105 Cr to ₹208 Cr. Meanwhile, core legacy API segments continue to face pricing pressure, suppressing the PAT margin to a thin 5.3%. A pivot from volume to value is rarely visible in the first year’s margins; the lag between capital deployment and cash generation tests investor patience. The firm also declared its first dividend in 23 years, tossing a ₹0.20 per share bone to shareholders. The foundational question remains: can Morepen survive the margin valley of death while its CDMO capacities scale?

Section 2 — Introduction

Morepen Laboratories is a four-decade-old pharmaceutical player navigating a mid-life identity shift. Originating as a classic bulk drug manufacturer, it is actively trying to rewrite its DNA into a diversified healthcare entity. The company now balances its historical Active Pharmaceutical Ingredients (API) manufacturing in Himachal Pradesh with a rapidly scaling medical devices division. While it exports to over 90 countries, the current corporate posture is overwhelmingly focused on breaking out of the generic pricing bloodbath and into the stickier, more lucrative realm of contract manufacturing.

Section 3 — Business Model: WTF Do They Even Do?

Morepen’s business is a tale of two very different treadmills.

First, the Pharma Business (70% of revenues), dominated by legacy APIs like Loratadine, Desloratadine, and Montelukast. They hold massive export market shares here. The problem? Selling legacy allergy and asthma drugs in a global market where Chinese manufacturers are treating pricing like a perpetual clearance sale. Volume goes up, realizations go down.

Second, the Medical Devices segment (30%). If you own a glucometer or a blood pressure monitor in India, there is a very high probability it bears the Dr. Morepen logo. They have sold over 17 million glucometers. This segment is growing faster and offers a hedge against the pharma pricing wars, essentially subsidizing the API segment’s margin compression.

Section 4 — Financials Overview

Figures are consolidated, in ₹ crore.

Revenue for Q4 FY26 was perfectly flat YoY at ₹485 Cr. However, Operating Profit cratered by 47% YoY, dragging PAT down to a mere ₹16 Cr. The margins are technically stabilizing, in the sense that they have stopped finding new ways to plunge.

Management noted in the investor presentation that their capacity expansion and long-duration CDMO programs lay the pathway toward a 20%+ EBITDA profile. Pathways usually involve a lot of uphill walking, and given the current 5% operating margin in Q4, we will be watching their stamina closely. Revenue growth without margin preservation is just expensive philanthropy.

Section 5 — Valuation Discussion: Fair Value Range Only

At a CMP of ₹45.30, the market is pricing in the CDMO turnaround rather than the current API reality.

• P/E Method: Using the